Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/pop.2020.0233 | DOI Listing |
Antimicrob Steward Healthc Epidemiol
January 2025
Division of Infectious Diseases & Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Background: The increase in severe acute respiratory coronavirus virus 2 (SARS-CoV-2) cases due to the omicron strain led to reduced acute care hospital beds at the Veterans Administration (VA) Hospital, North Texas; veterans with non-severe coronavirus disease 2019 (COVID-19) disease were managed at a community living center (CLC), a VA nursing home. The management of non-severe COVID-19 in VA nursing homes has not been extensively described.
Methods: We describe resident characteristics and outcomes, and infection control practices implemented during 2 COVID-19 outbreak periods (January 12-February 15, 2022, June 28-July 14, 2023).
Comput Biol Med
January 2025
Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Background: Sacubitril/valsartan (S/V) reduces mortality and hospitalization rates in patients with heart failure with reduced ejection fraction (HFrEF), but low adherence remains a challenge. Early initiation of S/V is recommended, yet no practical tool currently exists to effectively communicate its benefits to outpatients or assess patient stability before S/V initiation during hospitalization.
Methods: We collected data retrospectively from 527 HFrEF patients who started S/V between March 2017 and January 2020 at the National Taiwan University Hospital, with follow-up through September 2022.
Urogynecology (Phila)
January 2025
UConn Health, Farmington, CT.
Importance: The most used overactive bladder (OAB) medications are anticholinergics, which professional societies recommend avoiding in older patients given dementia risk. Cost prevents patients from switching to preferred beta-3 agonists. Mirabegron was the only beta-3 agonist eligible for the Centers for Medicare/Medicaid Services (CMS) 2023 Drug Negotiation Program (DNP).
View Article and Find Full Text PDFBMJ Open Qual
January 2025
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Attending to patient-reported outcomes (PROs) using data visualisation dashboards could enhance shared decision-making (SDM) and care delivery for serious chronic illnesses. However, few studies have evaluated real-world strategies and resulting implementation outcomes of PRO dashboards.
Method: From June 2020 to January 2022, we implemented an electronic health record (EHR)-integrated PRO dashboard for advanced cancer and chronic kidney disease.
Cancer
January 2025
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Background: The University of Kentucky Markey Cancer Center developed the data gathering and visualization platform Cancer InFocus (CIF) as a solution for cancer center catchment area surveillance. CIF was released in June 2022 and made available for use to other institutions through a no-cost licensing agreement. The purpose of this study was to evaluate the impact CIF has had on cancer centers since its release.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!